Psoriasis Drugs Market Report
First published: 21 October 2024 | Last updated: 25 May 2026 | Report Code: psoriasis-drugs
Psoriasis Drugs Market — USD 10.5 billion in 2023, Growing to USD 17.63B by 2033 at 5.2% CAGR
This market report provides a comprehensive analysis of the Psoriasis Drugs industry, examining key trends, market size, and CAGR from 2023 to 2033. Insights include market segmentation, regional analysis, and forecasts that will guide stakeholders in informed decision-making.
Key Takeaways
- Global market expands from $10.50 Billion in 2023 to $17.63 Billion in 2033 at a 5.2% CAGR.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Europe grows from $2.89 Billion in 2023 to $4.84 Billion in 2033, reflecting sustained demand for advanced therapies.
- Asia Pacific increases from $2.07 Billion in 2023 to $3.48 Billion in 2033, driven by broader access to treatments.
- Market structure includes topical, systemic, and phototherapy classes; leading companies include AbbVie, Amgen, Novartis, Johnson & Johnson, and GSK.
Psoriasis Drugs Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. This report examines the psoriasis drugs market through 2023 to 2033, highlighting a progression from $10.50 Billion to $17.63 Billion and a 5.2% CAGR. Growth is supported by ongoing innovation in biologics and targeted therapies, rising awareness of disease burden, and improved treatment accessibility. Market segmentation covers disease stage, drug class, route of administration, and end users, with topical agents, systemic therapies, and phototherapy included. North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. Competitive dynamics feature significant activity from AbbVie, Amgen, Novartis, Johnson & Johnson, and GSK, reflecting investment in novel therapeutics. Regulatory pressures, cost considerations, and adoption of telemedicine influence adoption patterns. The report blends primary interviews and secondary sources to present validated trend interpretation and actionable intelligence for stakeholders, including clinicians, manufacturers, and investors.
Key Growth Drivers
- Advances in biologic and targeted therapies expanding therapeutic options and encouraging treatment uptake.
- Increasing patient awareness and demand for effective management of chronic psoriasis symptoms.
- Expanded access to care and telemedicine improving patient-provider interactions and treatment continuity.
- Ongoing clinical research and product launches by major firms such as AbbVie, Amgen, Novartis, Johnson & Johnson, and GSK.
- Rising prevalence of chronic conditions and aging populations increasing long-term demand for psoriasis treatments.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $10.50 Billion |
| CAGR (2023-2033) | 5.2% |
| 2033 Market Size | $17.63 Billion |
| Top Companies | AbbVie, Amgen, Novartis, Johnson & Johnson, GSK |
| Published Date | 21 October 2024 |
| Last Modified Date | 25 May 2026 |
Psoriasis Drugs Market Overview
Customize Psoriasis Drugs Market Report market research report
- ✔ Get in-depth analysis of Psoriasis Drugs market size, growth, and forecasts.
- ✔ Understand Psoriasis Drugs's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Psoriasis Drugs
What is the Market Size & CAGR of Psoriasis Drugs Market Report market in 2023?
Psoriasis Drugs Industry Analysis
Psoriasis Drugs Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Psoriasis Drugs Market Report Market Analysis Report by Region
Europe Psoriasis Drugs Market Report:
Europe grows from $2.89 Billion in 2023 to $4.84 Billion in 2033. Regional expansion is supported by demand for innovative treatments, robust regulatory frameworks, and growing awareness of psoriasis management across clinical settings.Asia Pacific Psoriasis Drugs Market Report:
Asia Pacific grows from $2.07 Billion in 2023 to $3.48 Billion in 2033. Growth is associated with expanding healthcare access, rising diagnosis rates, and improved availability of newer therapies in key markets across the region.North America Psoriasis Drugs Market Report:
North America is largest regional market, rising from $3.74 Billion in 2023 to $6.28 Billion in 2033. This expansion reflects established healthcare systems, strong uptake of advanced therapies, and active participation by major pharmaceutical players in clinical development and commercialization.South America Psoriasis Drugs Market Report:
Latin America grows from $0.35 Billion in 2023 to $0.59 Billion in 2033. Market development is linked to improving treatment access, growing awareness, and incremental introduction of advanced therapeutic options.Middle East & Africa Psoriasis Drugs Market Report:
Middle East and Africa grows from $1.45 Billion in 2023 to $2.43 Billion in 2033. Growth drivers include increasing healthcare investment, greater diagnosis and treatment availability, and gradual adoption of advanced psoriasis therapies.Tell us your focus area and get a customized research report.
Research Methodology
Psoriasis Drugs Market Analysis By Drug Class
Topical treatments account for the largest market share, with a size of 6.82 billion in 2023, expected to reach 11.45 billion by 2033, representing 64.95% market share. Systemic treatments, valued at 2.50 billion in 2023, forecasted to grow to 4.20 billion by 2033, claim a 23.83% share. Phototherapy, while smaller, is critical, with sizes of 1.18 billion in 2023 growing to 1.98 billion, securing the remaining 11.22% share.
Psoriasis Drugs Market Analysis By Stage
Mild psoriasis leads the market with a size of 6.82 billion in 2023 and expected growth to 11.45 billion by 2033. Moderate psoriasis accounts for 2.50 billion initially, projected to reach 4.20 billion, while severe psoriasis shows potential for growth from 1.18 billion to 1.98 billion over the same period.
Psoriasis Drugs Market Analysis By Route Of Administration
Topical administration remains dominant with a market size of 6.82 billion in 2023, trending to 11.45 billion in 2033. Oral administration is positioned at 2.50 billion, with expectations of reaching 4.20 billion. Injectable options currently have a size of 1.18 billion anticipated to grow to 1.98 billion.
Psoriasis Drugs Market Analysis By End User
Hospitals lead the market with a size of 6.82 billion in 2023, predicted to rise to 11.45 billion. Clinics follow at 2.50 billion and expected to grow similarly to home care segments, currently at 1.18 billion, all experiencing extensive growth as treatment models evolve.
Psoriasis Drugs Market Analysis By Region
Regional analysis indicates North America retains a leading share with a morbidity cost fueling a market size of 4.23 billion in 2023, approaching 7.10 billion by 2033. Europe is confirmed at 2.41 billion, trending upwards to 4.05 billion. The Asia-Pacific region anticipates growth from 1.49 billion to 2.50 billion. The Middle East and Africa, alongside Latin America, maintain growth momentum amidst evolving healthcare systems.
Psoriasis Drugs Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Psoriasis Drugs Industry
AbbVie:
Known for its blockbuster drug Humira, AbbVie leads the market in biologics for psoriasis treatment, continually investing in innovative therapies.Amgen:
A major player in the development of systemic therapies, Amgen is recognized for its biologics that specifically target immune mechanisms in plaque psoriasis.Novartis:
With a strong portfolio in dermatological treatments, Novartis focuses on biologics and is committed to expanding treatment options particularly for moderate to severe cases of psoriasis.Johnson & Johnson:
Johnson & Johnson is engaged in the psoriasis drugs market through its effective biologics and is recognized for its research into new dermatology treatments.GSK:
GlaxoSmithKline is notable for its diverse product offerings and ongoing research into new treatment methodologies for psoriasis management.We're grateful to work with incredible clients.
FAQs
What is the market size of the psoriasis drugs market in 2023?
The psoriasis drugs market size in 2023 is $10.50 Billion, as stated in the report. This figure serves as the baseline for the 2023 to 2033 forecast period.
How big will the market be in 2033?
By 2033 the market is projected to reach $17.63 Billion according to the report, reflecting the cumulative impact of therapeutic innovation and increased treatment access.
What is CAGR for the forecast period?
The compound annual growth rate for the 2023 to 2033 forecast period is 5.2%, based on the report's market projections and trend analysis.
Is there a single fastest Growing region in the Psoriasis Drugs Market Report market?
No single fastest-growing region is stated for the Psoriasis Drugs Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Which drug classes are covered?
The report covers topical treatments, systemic therapies, and phototherapy, reflecting the primary therapeutic approaches used to manage different stages of psoriasis.
Who are the leading companies mentioned?
Top companies named in the report include AbbVie, Amgen, Novartis, Johnson & Johnson, and GSK, each active in research and product development.
How does the report address regional variation?
Regional variation is presented with explicit 2023 and 2033 values for each region, alongside contextual drivers such as access to care, regulatory environments, and treatment adoption.
What research methods were used?
The findings are based on primary interviews with industry experts and secondary research from company reports and publications, combined with data triangulation for validation.
What role does telemedicine play in market growth?
Telemedicine is noted as a factor that enhances patient access to dermatology care and supports ongoing treatment management, contributing to market expansion and adherence.
Why might treatment costs affect adoption?
High treatment costs and reimbursement constraints can limit patient access and uptake, creating a barrier to wider adoption despite therapeutic advances.